The activity of NATs can vary significantly among individuals due to genetic polymorphisms. These genetic variations can influence the rate at which drugs and toxins are metabolized. For instance, people can be classified as "slow acetylators" or "fast acetylators" based on their NAT2 genotype. Slow acetylators are at an increased risk for certain drug toxicities and adverse effects, while fast acetylators may require higher doses of some medications to achieve therapeutic effects.
